glucagon-like-peptide-1-(7-36)amide and Celiac-Disease

Topics: Animals; Blood Glucose; Celiac Disease; Digestive System; Duodenal Ulcer; Gastric Inhibitory Polypeptide; Gastrointestinal Diseases; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glucose Tolerance Test; Humans; Ileum; Insulin; Intestine, Small; Islets of Langerhans; Jejunum; Peptide Fragments; Peptides; Vagotomy

Eight patients with biopsy-verified coeliac disease were investigated after remission on a gluten-free diet. A 50-g oral glucose load (OGTT) and an intravenous glucose infusion (IVGI) giving the same plasma glucose profile as the OGTT were carried out. The relation between gastric inhibitory polypeptide (GIP) plasma levels after oral glucose and the insulin release during OGTT and IVGI were studied. Plasma GIP concentration in the fasting state and the increase in plasma GIP during OGTT were significantly lower than in a group of eight healthy volunteers. However, the insulin potentiation during OGTT, the incretin effect, was normal. The results indicate the existence of other incretins than GIP. These are probably released from the distal small bowel in patients with coeliac disease.

Topics: Adult; Blood Glucose; Celiac Disease; Female; Gastric Inhibitory Polypeptide; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glucose Tolerance Test; Humans; Insulin; Insulin Secretion; Male; Middle Aged; Peptide Fragments; Peptides